Tackling hepatitis C in Australia: The third national strategy

The Lancet Infectious Diseases

Volumn 12, Issue 3, 2012, Pages 172-173

  Maher, Lisa ^a  

^a UNIVERSITY OF NEW SOUTH WALES   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

AUSTRALIA; DISEASE SURVEILLANCE; HEALTH CARE ACCESS; HEALTH CARE PLANNING; HEALTH PROMOTION; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; INTRAVENOUS DRUG ABUSE; LETTER; LIVER CANCER; LIVER FAILURE; NATIONAL HEALTH SERVICE; PREVALENCE; PREVENTIVE HEALTH SERVICE; PRIORITY JOURNAL; SCREENING; WORLD HEALTH ORGANIZATION;

AUSTRALIA; HEPATITIS C; HUMANS;

EID: 84857185220     PISSN: 14733099     EISSN: 14744457     Source Type: Journal    
DOI: 10.1016/S1473-3099(11)70355-3     Document Type: Letter

References (12)

1. Shepard CW, Finelli L, Alter MJ Global epidemiology of hepatitis C virus infection. Lancet Infect Dis 2005, 5:558-567.
2. Volk ML, Tocco R, Saini S, et al. Public health impact of antiviral therapy for hepatitis C in the United States. Hepatology 2009, 50:1750-1755.
3. Lettmeier B, Muhlberger N, Schwarzer R, et al. Market uptake of new antiviral drugs for the treatment of hepatitis C. J Hepatol 2008, 49:528-536.
4. Joshi D, O'Grady J, Dieterich D, et al. Increasing burden of liver disease in patients with HIV infection. Lancet 2011, 377:1198-1209.
5. Viral hepatitis WHO, (accessed Nov 26, 2011). http://apps.who.int/gb/ebwha/pdf_files/WHA63/A63_15-en.pdf.
6. Morris K Tackling hepatitis C: a tale of two countries. Lancet 2011, 377:1227-1228.
7. HIV, viral hepatitis and sexually transmissible infections in Australia. Annual Surveillance Report 2010 National Centre in HIV Epidemiology and Clinical Research, (accessed April 21, 2011). http://www.med.unsw.edu.au/NCHECRweb.nsf/resources/SurvRep07/$file/ASR2010-rev1.pdf.
8. Maher L, Jalaludin B, Chant KG, et al. Incidence and risk factors for hepatitis C seroconversion in injecting drug users in Australia. Addiction 2006, 101:1499-1508.
9. Australia NSP Survey National Data Report 2005-2009. Prevalence of HIV, HCV and injecting and sexual behaviour among IDUs at needle and syringe programs National Centre in HIV Epidemiology and Clinical Research, (accessed April 21, 2011). http://www.med.unsw.edu.au/NCHECRweb.nsf/resources/NSP_Complete2/$file/ANSP.NDR.2005_2009.pdf.
10. Third National Hepatitis C Strategy 2010-2103 Australian Government Department of Health and Ageing, (accessed Dec 5, 2011). http://www.health.gov.au/internet/main/publishing.nsf/Content/ohp-national-strategies-2010-hcv/$File/hcv.pdf.
11. Gane EJ, Stedman CA, Hyland RH. Once Daily PSI-7977 plus RBV: pegylated interferon-alfa not required for complete rapid viral response in treatment-naive patients with HCV GT2 or GT3. 62nd Annual Meeting of the American Association for the Study of Liver Disease (AASLD 2011); San Francisco; Nov 4-8, 2011. Abstract 34.
12. National Blood-borne Virus and Sexually Transmissible Infections Surveillance and Monitoring Plan Communicable Diseases Network of Australia, (accessed Jan 16, 2012). http://www.health.gov.au/internet/main/publishing.nsf/Content/095DD5019EA33DBECA2579600079042D/$File/monitoring-plan.pdf.